Cary Claiborne, CEO, Adial Pharmaceuticals, discusses AD04’s development timeline and next steps towards approval for alcohol use disorder.
Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback